XML 51 R40.htm IDEA: XBRL DOCUMENT v3.4.0.3
Segment Information (Details) - USD ($)
$ in Millions
3 Months Ended
Mar. 31, 2016
Mar. 31, 2015
Document Period End Date Mar. 31, 2016  
Revenue $ 4,865.1 $ 4,644.7
Collaboration and other revenue 182.3 196.1
Income before income taxes 566.8 617.9
Acquired in-process research and development 0.0 (256.0)
Asset impairment, restructuring, and other special charges (131.4) (108.0)
Foreign Currency Transaction Gain (Loss), Realized (203.9) 0.0
Nonoperating Income (Expense) (149.0) 92.7
Cost of sales (1,323.0) (1,192.7)
Marketing, selling, and administrative (1,473.9) (1,523.5)
Debt extinguishment loss 0.0 0.0
Neuroscience [Member]    
Revenue 643.7 725.3
Endocrinology [Member]    
Revenue 1,756.7 1,626.3
Oncology [Member]    
Revenue 894.5 759.0
Cardiovascular [Member]    
Revenue 754.2 715.2
Animal Health [Member]    
Income before income taxes 147.6 115.0
Other pharmaceuticals [Member]    
Revenue 61.4 69.1
Animal Health Products [Member]    
Revenue 754.6 749.8
Human Pharmaceutical Products [Member]    
Revenue 4,110.5 3,894.9
Income before income taxes 927.0 1,083.1
Operating Segments [Member]    
Income before income taxes 1,074.6 1,198.1
Corporate, Non-Segment [Member]    
Acquired in-process research and development 0.0 (256.0)
Asset impairment, restructuring, and other special charges (131.4) (108.0)
Foreign Currency Transaction Gain (Loss), Realized (203.9) 0.0
Amortization of Intangible Assets (172.5) (152.7)
Other Endocrinology [Member] | Endocrinology [Member]    
Revenue 204.0 166.2
Humalog [Member] | Endocrinology [Member]    
Revenue 606.3 684.0
Humulin [Member] | Endocrinology [Member]    
Revenue 356.4 315.7
Forteo [Member] | Endocrinology [Member]    
Revenue 318.6 293.0
Evista [Member] | Endocrinology [Member]    
Revenue 33.4 66.8
Trulicity [Member] [Member] | Endocrinology [Member]    
Revenue 143.6 18.3
Trajenta (BI) [Member] | Endocrinology [Member]    
Collaboration and other revenue 94.4 82.3
Cymbalta [Member] | Neuroscience [Member]    
Revenue 198.7 287.0
Zyprexa [Member] | Neuroscience [Member]    
Revenue 212.8 219.5
Strattera [Member] | Neuroscience [Member]    
Revenue 188.1 173.7
Other Neuroscience [Member] | Neuroscience [Member]    
Revenue 44.1 45.1
Alimta [Member] | Oncology [Member]    
Revenue 564.2 573.0
Erbitux [Member]    
Revenue 168.1 88.2
Collaboration and other revenue 26.6 74.4
Erbitux [Member] | Oncology [Member]    
Revenue 168.1 88.2
Effient [Member]    
Revenue   121.8
Effient [Member] | Cardiovascular [Member]    
Revenue 131.5 121.8
Other Oncology [Member] | Oncology [Member]    
Revenue 31.2 30.3
Cialis [Member] | Cardiovascular [Member]    
Revenue 576.7 538.3
Other Cardiovascular [Member] | Cardiovascular [Member]    
Revenue 46.0 55.1
Cyramza [Member] | Oncology [Member]    
Revenue 131.0 67.5
Fair Value Adjustment to Inventory [Member] | Corporate, Non-Segment [Member]    
Cost of sales 0.0 $ (63.5)
Long-term Debt [Member] | Corporate, Non-Segment [Member]    
Nonoperating Income (Expense) $ 0.0